九洲药业：控股子公司九洲生物获得拉考沙胺片药品注册证书

Group 1 - The core point of the article is that Jiuzhou Pharmaceutical (603456) announced that its subsidiary Jiuzhou Biotech has received the drug registration certificate for Lacosamide Tablets from the National Medical Products Administration, indicating a significant regulatory milestone for the company [1] - Lacosamide Tablets are indicated for the adjunctive treatment of partial-onset seizures in patients aged 4 years and older, expanding the company's product offerings in the epilepsy treatment market [1] - The drug was originally developed by UCB Pharma and was first launched in the European Union in August 2008, highlighting its established presence in international markets [1] Group 2 - The domestic market sales of Lacosamide Tablets in 2022 amounted to approximately RMB 174 million, indicating a substantial market opportunity for Jiuzhou Biotech [1] - Jiuzhou Biotech has invested approximately RMB 11.39 million in the research and development of Lacosamide Tablets, reflecting the company's commitment to developing its product pipeline [1] - Other manufacturers that have obtained the drug registration certificate in China include Jiangxi Qingfeng Pharmaceutical Co., Ltd. and Shaanxi Buchang Pharmaceutical Co., Ltd. (603858), indicating a competitive landscape in the domestic market [1]